Dr. Reddy’s Laboratories announced the launch of Zoledronic Acid Injection, the generic version of NovartisZometa.

Zometa is a bisphosphonate indicated for hypercalcemia of malignancy, and as adjunct in multiple myeloma and bone metastases of solid tumors. Zometa inhibits osteoclastic activity and induces osteoclast apoptosis. It also blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Also, it inhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factors released by tumors.

Zoledronic Acid Injection is available in a 4mg/5mL concentration as single-use vials.

For more information call (908) 203-4900 or visit www.drreddys.com.